You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MOR208

Showing 1 - 25 of 39
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)

Recruiting
  • CNS Lymphoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Aug 10, 2022

Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jul 12, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Duarte (procedure, biological, drug)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Biospecimen Collection
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 30, 2023

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Rochester (procedure, drug, biological)

Not yet recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biopsy
  • +10 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 9, 2023

Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6

Not yet recruiting
  • Grade 3b Follicular Lymphoma
  • +5 more
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Jun 6, 2023

Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)

Not yet recruiting
  • Chronic Graft Versus Host Disease
  • +2 more
  • Biopsy
  • +11 more
  • Duarte, California
    City of Hope Medical Center
Aug 7, 2023

Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial

Not yet recruiting
  • Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
  • Polymorphic Post-Transplant Lymphoproliferative Disorder
  • Biopsy
  • +5 more
  • New Brunswick, New Jersey
  • +2 more
Mar 23, 2023

DLBCL, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 12, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide

Completed
Has Results
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +2 more
  • Tafasitamab
  • +2 more
  • Jacksonville, Florida
  • +16 more
Dec 10, 2021

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

DLBCL Trial in Belgium, France (Tafasitamab, Lenalidomide, Rituximab)

Recruiting
  • DLBCL
  • Brussels, Belgium
  • +14 more
Mar 3, 2022

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • Bone Marrow Aspiration and Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

DLBCL Trial in Houston (Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

DLBCL Trial (Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day

Approved for marketing
  • DLBCL
  • Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression
  • (no location specified)
Aug 26, 2020

Diffuse Large B-cell Lymphoma Trial in Worldwide (MOR00208, Lenalidomide)

Active, not recruiting
Has Results
  • Diffuse Large B-cell Lymphoma
  • Bakersfield, California
  • +52 more
Sep 1, 2021

Lenalidomide Monotherapy in R/R DLBCL

Completed
  • Diffuse Large B Cell Lymphoma
    • Rochester, Minnesota
    • +56 more
    Aug 23, 2022

    Diffuse Large B Cell Lymphoma Trial in Worldwide (Tafasitamab, Lenalidomide)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Dallas, Texas
    • +29 more
    Jan 20, 2023

    Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial

    Active, not recruiting
    • Contiguous Stage II Small Lymphocytic Lymphoma
    • +11 more
    • MOR00208
    • +2 more
    • Columbus, Ohio
      The Ohio State University Comprehensive Cancer Center
    Feb 24, 2022

    Diffuse Large B-cell Lymphoma Trial in Worldwide (Rituximab (RTX), Tafasitamab, Bendamustine (BEN))

    Active, not recruiting
    • Diffuse Large B-cell Lymphoma
    • Rituximab (RTX)
    • +2 more
    • Anaheim, California
    • +157 more
    Aug 1, 2022

    NASH - Nonalcoholic Steatohepatitis Trial in Worldwide (VK2809, Placebos)

    Recruiting
    • NASH - Nonalcoholic Steatohepatitis
    • Birmingham, Alabama
    • +107 more
    Mar 1, 2022

    Systemic Therapies for R/R DLBCL

    Completed
    • Diffuse Large B Cell Lymphoma
      • Scottsdale, Arizona
      • +165 more
      Oct 12, 2021

      Acute Lymphoblastic Leukemia Trial in Columbus, Memphis, Houston (MOR00208 (formerly Xmab5574))

      Terminated
      Has Results
      • Acute Lymphoblastic Leukemia
      • MOR00208 (formerly Xmab5574)
      • Columbus, Ohio
      • +2 more
      Feb 20, 2018

      Diffuse Large B-cell Lymphoma Trial in Worldwide (Tafasitamab, Lenalidomide, Rituximab)

      Recruiting
      • Diffuse Large B-cell Lymphoma
      • Birmingham, Alabama
      • +408 more
      Aug 23, 2022

      Tetralogy of Fallot Trial (Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON])

      Not yet recruiting
      • Tetralogy of Fallot
      • Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
      • (no location specified)
      Jan 10, 2022

      Pulmonary Disease, Chronic Obstructive Trial in Worldwide (BEA 2180 BR, Tiotropium Bromide, Placebo)

      Completed
      Has Results
      • Pulmonary Disease, Chronic Obstructive
      • BEA 2180 BR
      • +2 more
      • Jasper, Alabama
      • +177 more
      Jul 30, 2021